Bile-tagged 3D magnetic resonance colonography after exclusive intravenous administration of gadobenate dimeglumine, a contrast agent with partial hepatobiliary excretion

Investigative Radiology

Volumn 36, Issue 10, 2001, Pages 619-623

  Knopp, Michael V ^a,b   Giesel, Frederik L ^a,b   Radeleff, Jannis ^b   Von Tengg Kobligk, Hendrik ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Hepatobiliary excretion; Intraluminal contrast; MR colonography; Virtual endoscopy

Indexed keywords

GADOBENATE DIMEGLUMINE; GLUCAGON; SCOPOLAMINE BUTYL BROMIDE;

ADULT; ARTICLE; COLON RADIOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EXCRETION; FOLLOW UP; HEPATOBILIARY SYSTEM; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; MAGNETIC RESONANCE ANGIOGRAPHY; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING;

EID: 0034788343     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200110000-00008     Document Type: Article

References (21)

1. Preliminary assessment of three-dimensional magnetic resonance imaging for various colonic disorders
2. Virtual endoscopic colonography based on 3D MRI
3. A comparative study between Gd-DTPA and oral magnetic particles (OMP) as gastrointestinal (GI) contrast agents for MRI of the abdomen
4. In vivo exoscopic and endoscopic MR imaging of the colon
5. Helical CT colonography (virtual colonoscopy): The challenge that exists between advancing technology and generalizability
6. Automated polyp detection at CT colonography: Feasibility assessment in a human population
7. Gadobenate dimeglumine (Gd-BOPTA): An overview
8. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers
9. Hepatocellular carcinoma: Correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings
10. Contrast agents for MRA: Future directions
11. Hepatocyte targeting with Gd-EOB-DTPA: Potential application for gene therapy
12. Small intestine transit time in the normal small bowel study
13. Comparison of methods for acceleration of small intestinal radiographic examination
14. Fibre and bowel transit times
15. Bowel transit-times in two populations experiencing similar colon-cancer risks
16. Use of nutritional support formula as a gastrointestinal contrast agent for MRI
17. Synergistic effect between iron and gadolinium in MRI
18. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: Results of multicenter studies in Europe and the USA
19. MultiHance in the assessment of intracranial tumors: Results of phase II clinical studies
20. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance)
21. Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance), a new magnetic resonance imaging contrast medium